Correction: Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study

Takahiro WakasakiI; Tomomi Manako; Ryuji YasumatsuI; Hirotaka Hara; Satoshi Toh; Muneyuki Masuda; Moriyasu YamauchiID; Yuichiro Kuratomi; Emi Nishimura; Toranoshin Takeuchi; Mioko Matsuo; Rina Jiromaru; Kazuki Hashimoto; Noritaka Komune; Takashi Nakagawa

doi:10.1371/journal.pone.0303720

Correction: Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study

PLoS One. 2024 May 9;19(5):e0303720. doi: 10.1371/journal.pone.0303720. eCollection 2024.

Authors

Takahiro WakasakiI, Tomomi Manako, Ryuji YasumatsuI, Hirotaka Hara, Satoshi Toh, Muneyuki Masuda, Moriyasu YamauchiID, Yuichiro Kuratomi, Emi Nishimura, Toranoshin Takeuchi, Mioko Matsuo, Rina Jiromaru, Kazuki Hashimoto, Noritaka Komune, Takashi Nakagawa

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0271907.].

Copyright: © 2024 WakasakiI et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Publication types

Published Erratum